1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 NS3/4A Protease Inhibitors
1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
1.2.4 NS5A Inhibitors
1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors
1.3 Market by Application
1.3.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Direct-acting Antiviral Drugs Market Perspective (2017-2028)
2.2 Direct-acting Antiviral Drugs Growth Trends by Region
2.2.1 Direct-acting Antiviral Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Direct-acting Antiviral Drugs Historic Market Size by Region (2017-2022)
2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Region (2023-2028)
2.3 Direct-acting Antiviral Drugs Market Dynamics
2.3.1 Direct-acting Antiviral Drugs Industry Trends
2.3.2 Direct-acting Antiviral Drugs Market Drivers
2.3.3 Direct-acting Antiviral Drugs Market Challenges
2.3.4 Direct-acting Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue
3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2017-2022)
3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue
3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio
3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2021
3.5 Direct-acting Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Direct-acting Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Direct-acting Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Direct-acting Antiviral Drugs Breakdown Data by Type
4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2017-2022)
4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2023-2028)
5 Direct-acting Antiviral Drugs Breakdown Data by Application
5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2017-2022)
5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Direct-acting Antiviral Drugs Market Size (2017-2028)
6.2 North America Direct-acting Antiviral Drugs Market Size by Type
6.2.1 North America Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
6.2.2 North America Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
6.2.3 North America Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
6.3 North America Direct-acting Antiviral Drugs Market Size by Application
6.3.1 North America Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
6.3.2 North America Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
6.3.3 North America Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
6.4 North America Direct-acting Antiviral Drugs Market Size by Country
6.4.1 North America Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
6.4.2 North America Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Direct-acting Antiviral Drugs Market Size (2017-2028)
7.2 Europe Direct-acting Antiviral Drugs Market Size by Type
7.2.1 Europe Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
7.2.2 Europe Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
7.2.3 Europe Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
7.3 Europe Direct-acting Antiviral Drugs Market Size by Application
7.3.1 Europe Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
7.3.2 Europe Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
7.3.3 Europe Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
7.4 Europe Direct-acting Antiviral Drugs Market Size by Country
7.4.1 Europe Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
7.4.2 Europe Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2017-2028)
8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type
8.2.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application
8.3.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region
8.4.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Direct-acting Antiviral Drugs Market Size (2017-2028)
9.2 Latin America Direct-acting Antiviral Drugs Market Size by Type
9.2.1 Latin America Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
9.3 Latin America Direct-acting Antiviral Drugs Market Size by Application
9.3.1 Latin America Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country
9.4.1 Latin America Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2017-2028)
10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type
10.2.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application
10.3.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country
10.4.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.1.5 AbbVie Inc. Recent Developments
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Direct-acting Antiviral Drugs Introduction
11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.2.5 GSK Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Direct-acting Antiviral Drugs Introduction
11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.4.5 Merck Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Direct-acting Antiviral Drugs Introduction
11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.5.5 Novartis Recent Developments
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.6.5 Beximco Pharmaceuticals Recent Developments
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Direct-acting Antiviral Drugs Introduction
11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.7.5 Roche Recent Developments
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Details
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.8.5 Bristol-Myers Squibb Company Recent Developments
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.9.5 Gilead Sciences Recent Developments
11.10 Janssen (Johnson & Johnson)
11.10.1 Janssen (Johnson & Johnson) Company Details
11.10.2 Janssen (Johnson & Johnson) Business Overview
11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.10.5 Janssen (Johnson & Johnson) Recent Developments
11.11 Vertex Pharmaceuticals
11.11.1 Vertex Pharmaceuticals Company Details
11.11.2 Vertex Pharmaceuticals Business Overview
11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.11.5 Vertex Pharmaceuticals Recent Developments
11.12 Natco Pharma
11.12.1 Natco Pharma Company Details
11.12.2 Natco Pharma Business Overview
11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.12.5 Natco Pharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
